help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-0233
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/3/1644    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rouget, C.
Right arrow Articles by Leroy, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rouget, C.
Right arrow Articles by Leroy, M. J.
Related Collections
Right arrow Female Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 3 1644-1650
Copyright © 2005 by The Endocrine Society

ß3-Adrenoceptor Is the Predominant ß-Adrenoceptor Subtype in Human Myometrium and Its Expression Is Up-Regulated in Pregnancy

C. Rouget, M. Bardou, M. Breuiller-Fouché, C. Loustalot, H. Qi, E. Naline, T. Croci, D. Cabrol, C. Advenier and M. J. Leroy

Unité Propre de Recherche de l’Enseignement Supérieur EA220–Pharmacology (C.R., M.B., H.Q., E.N., C.A.), Unité de Formation et de Recherche Biomédicale des Saints Pères, 75006 Paris, France; Institut National de la Santé et de la Recherche Médicale U427 (C.R., M.B.-F., H.Q., D.C., M.J.L.) and Department of Gynecology (D.C.), Port-Royal Maternity Hospital, 75014 Paris, France; Department of Gynecology (C.L.), Centre Hospitalier Universitaire du Bocage, 21000 Dijon, France; Sanofi-Aventis Research Center (T.C.), 20137 Milan, Italy; Laboratory of Cardiovascular Physiopathology and Pharmacology (M.B.), Faculty of Medicine, 21079 Dijon, France

Address all correspondence and requests for reprints to: Céline Rouget, Unité Propre de Recherche de l’Enseignement Supérieur EA220–Pharmacology, Unité de Formation et de Recherche Biomédicale des Saints Pères, 45 rue des Saints Pères, F-75006 Paris, France. E-mail: celine.rouget{at}univ-paris5.fr.

To assess whether pregnancy might influence the functionality and expression of human myometrial ß2- and ß3-adrenoceptors 2- and ß3-AR), we performed functional, binding, Western blot, and molecular biology experiments in human nonpregnant and near-term pregnant myometrium. Inhibition of spontaneous contractions induced by a ß3-AR agonist, SR 59119A, was significantly greater in pregnant, compared with nonpregnant, myometrial strips (E'max = 61 ± 5% vs. 44 ± 5% for pregnant and nonpregnant myometrium, respectively), whereas salbutamol, a ß2-AR agonist, was significantly less efficient in pregnant, compared with nonpregnant, myometrium (Emax = 29 ± 4 vs. 54 ± 8%). Although two populations of binding sites corresponding to ß2- and ß3-AR were identified in both nonpregnant and pregnant myometrium, we found a clear predominance of the ß3-AR subtype. Moreover, ß3-AR binding sites were up-regulated 2-fold in myometrium at the end of pregnancy. Both ß2- and ß3-AR mRNA were expressed in human nonpregnant and pregnant myometrium. Contrary to ß2-AR, the expression of the ß3-AR transcripts and immunoreactive proteins was increased in pregnant, compared with nonpregnant, myometrium. Such compelling data suggest a predominant role for ß3-AR in the regulation of human myometrium contractility, especially at the end of pregnancy, which might have important consequences for the clinical management of preterm labor.




This article has been cited by other articles:


Home page
Biol. Reprod.Home page
F. Lirussi, Z. Rakotoniaina, S. Madani, F. Goirand, M. Breuiller-Fouche, M.-J. Leroy, P. Sagot, J. J. Morrison, M. Dumas, and M. Bardou
ADRB3 Adrenergic Receptor Is a Key Regulator of Human Myometrial Apoptosis and Inflammation During Chorioamnionitis
Biol Reprod, March 1, 2008; 78(3): 497 - 505.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Croci, R. Cecchi, P. Marini, C. Rouget, N. Viviani, G. Germain, F. Guagnini, Y. Fradin, L. Descamps, M. Pascal, et al.
In Vitro and in Vivo Pharmacological Characterization of Ethyl-4-{trans-4-[((2S)-2-hydroxy-3-{4-hydroxy-3[(methylsulfonyl)amino]-phenoxy}propyl) Amino]cyclohexyl}benzoate Hydrochloride (SAR150640), a New Potent and Selective Human beta3-Adrenoceptor Agonist for the Treatment of Preterm Labor
J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1118 - 1126.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
C. Rouget, O. Barthez, F. Goirand, M.J. Leroy, M. Breuiller-Fouche, Z. Rakotoniaina, P. Guerard, E.J. Morcillo, C. Advenier, P. Sagot, et al.
Stimulation of the ADRB3 Adrenergic Receptor Induces Relaxation of Human Placental Arteries: Influence of Preeclampsia
Biol Reprod, January 1, 2006; 74(1): 209 - 216.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society